ALUNBRIG.com
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
40 Landsdowne St, Cambridge, Massachuset...Phone Number
(844) 817-6468Website
www.alunbrig.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About ALUNBRIG.com
ALUNBRIG® (brigatinib) is a prescription medication used for the treatment of adults diagnosed with ALK+ metastatic non-small cell lung cancer (NSCLC). It is intended for patients who have experienced disease progression after crizotinib or are newly diagnosed with this specific type of lung cancer. The medication aims to provide a manageable treatment option with a dosing schedule that minimally impacts daily life. ALUNBRIG is primarily focused on supporting patients with lung cancer and is designed to lead to a significant reduction in tumor volume.Explore more
Popular SearchesALUNBRIG.comAlunbrigSIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ALUNBRIG.com your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if ALUNBRIG.com had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when ALUNBRIG.com launches new products
Check if ALUNBRIG.com has recently received funding, and reach out quickly before it becomes old news!
ALUNBRIG.com, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ALUNBRIG.com is spiking on competitors!
Earning: See what the market has to say on ALUNBRIG.com recently announced quarterly report
Funding: Get notified immidiatlly once ALUNBRIG.com has new funding data
Congratulate Masked Content for being promoted to Masked Content at ALUNBRIG.com
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined ALUNBRIG.com as Masked Content
Find more new buyers
Compare Similar Companies to ALUNBRIG.com
Compare insights from companies similar to ALUNBRIG.com, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
ALUNBRIG.com is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ALUNBRIG.com is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ALUNBRIG.com.
ALUNBRIG.com Tech Stack
ALUNBRIG.com News & Media
希少な重篤肺がんと診断された患者に対するファーストライン治療としての武田薬品のALUNBRIG®（ブリガチニブ）を米国FDAが承認
米マサチューセッツ州ケンブリッジ & 大阪--(BUSINESS WIRE)--（ビジネスワイヤ） -- 武田薬品工業株式会社（TSE:4502/NYSE:TAK）は本日、ALUNBRIG（ブリガチニブ）について、米国食品医薬品局（FDA）認可の検査で未分化リンパ腫キナーゼ遺伝子変異陽性（ALK陽性）転移性非小細胞肺がん（NSCLC）と診断された成人患者に対する治療薬として、FDAが承認したと発表しました。今回の承認により、ALUNBRIGの適応症が拡大され、ファーストライン治療が追加されました。ALUNBRIGは強力で選択的な次世代チロシンキナーゼ阻害剤（TKI）であり、ALKの分子変異を標的として阻害するように設計されています。 武田薬品のグローバル・オンコロジー・ビジネス・ユニットのプレジデントを務めるテレサ・ビテッティは、次のように述べています。「当社は、初発ALK陽性NSCLC患者さん、特に脳転移を有する患者さんにおいて、ALUNBRIGの良好な結果が示されたことを大変うれしく思います。武田薬品はNSCLCの広い治療状況に対応する充実した臨床開発プログラムと進行中の試La FDA de EE. UU. aprueba ALUNBRIG® (brigatinib) de Takeda como opción de tratamiento de primera línea para pacientes diagnosticados con cáncer de pulmón raro y grave
CAMBRIDGE, Massachusetts y OSAKA, Japón--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (Bolsa de Valores de Tokio:4502/Bolsa de Valores de Nueva York:TAK) anunció hoy que la Administración de Alimentos y Medicamentos (FDA) de EE. UU. aprobó ALUNBRIG (brigatinib) para pacientes adultos con cáncer de pulmón no microcítico metastásico (NSCLC) positivo para cinasa de linfoma anaplásico (ALK+) detectado mediante una evaluación aprobada por la FDA. Esta aprobación amplía la indicación actualUS-amerikanische FDA erteilt Zulassung für Takedas ALUNBRIG® (Brigatinib) als Erstlinienbehandlung für Patienten mit seltenen und schweren Formen von Lungenkrebs
CAMBRIDGE, Massachusetts, und OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) gab heute bekannt, dass die US-amerikanische Arzneimittelbehörde (Food and Drug Administration, FDA) die Zulassung für ALUNBRIG (Brigatinib) erteilt hat, und zwar für erwachsenen Patienten mit Anaplastische-Lymphom-Kinase (ALK)-positivem, metastasiertem nicht-kleinzelligem Lungenkrebs (NSCLC), der durch einen von der FDA anerkannten Test festgestellt wurde. Diese Zulassung erweFDA dos EUA aprova ALUNBRIG® (brigatinibe) da Takeda como opção de tratamento de primeira linha para pacientes diagnosticados com forma rara e grave de câncer de pulmão
CAMBRIDGE, Massachusetts e OSAKA, Japão--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) anunciou hoje que o FDA (Food and Drug Administration) dos EUA aprovou o ALUNBRIG (brigatinibe) para pacientes adultos com câncer de pulmão metástico de não-pequenas células (CPNPC) positivo para quinase de linfoma anaplásico (ALK+), conforme detectado por um teste aprovado pelo FDA. Esta aprovação expande a indicação atual do ALUNBRIG para incluir o cenário de primeira linha. O A
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ALUNBRIG.com
Sign Up For FreeTo access detailed company insights
ALUNBRIG® (brigatinib) is a prescription medication used for the treatment of adults diagnosed with ALK+ metastatic non-small cell lung cancer (NSCLC). It is intended for patients who have experienced disease progression after crizotinib or are newly diagnosed with this specific type of lung cancer. The medication aims to provide a manageable treat... Read More
